The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,549,732 in first-year total cost, median $517,321.
Most frequent study sections
- Special Emphasis Panel[ZCA1 TCRB-J (M1)]5
- Special Emphasis Panel[ZCA1 TCRB-D (O1)]4
- Special Emphasis Panel[ZCA1 TCRB-J (J1)]4
Most frequent institutions
- UNIVERSITY OF WASHINGTON2
- CASE WESTERN RESERVE UNIVERSITY1
- CORNELL UNIVERSITY1
- DANA-FARBER CANCER INST1
- GEORGIA INSTITUTE OF TECHNOLOGY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Rational generation of high-performance recombinant antibodies to post-translational modifications1R21CA246457-01A1 | HATTORI, TAKAMITSU | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $620,370 | ZCA1 |
| 2020 | Highly specific, amplification-free, single-molecule counting of rare methylated DNA cancer biomarkers1R21CA225493-01A1 | TEWARI, MUNEESHWALTER, NILS G | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $608,541 | ZCA1 |
| 2020 | Spatiotemporal Epitranscriptome Editing Technology1R21CA247638-01 | LIANG, FU-SEN | CASE WESTERN RESERVE UNIVERSITY, OH | $602,140 | ZCA1 |
| 2020 | High-content functional cancer drug testing on micro-cuboidal tumor dissections1R21CA251952-01 | FOLCH, ALBERT | UNIVERSITY OF WASHINGTON, WA | $601,999 | ZCA1 |
| 2020 | Phenotypic assay for drug discovery and personalized medicine based on real-time vibrational spectroscopy enhanced by plasmonic metasurfaces1R21CA251052-01 | SHVETS, GENNADY | CORNELL UNIVERSITY, NY | $598,729 | ZCA1 |
| 2020 | Fractionation and Profiling of Heterogeneous Circulating Tumor Cells Using a Hyperuniform- Structured Microchip1R21CA240185-01A1 | LI, WEI | TEXAS TECH UNIVERSITY, TX | $553,092 | ZCA1 |
| 2020 | Nanotechnology Enabled Selection of MHC-Peptide Ligands to Personalize Cancer Therapy1R21CA240220-01A1 | ALEXANDRAKIS, GEORGIOS | UNIVERSITY OF TEXAS ARLINGTON, TX | $517,321 | ZCA1 |
| 2020 | Tools for DUB Drug Discovery1R21CA247671-01 | BUHRLAGE, SARA JMARTO, JARROD A. | DANA-FARBER CANCER INST, MA | $323,910 | ZCA1 |
| 2020 | A microfluidic cell culture platform for personalizing pancreatic cancer therapies1R21CA236612-01A1 | REVZIN, ALEXANDER | MAYO CLINIC ROCHESTER, MN | $290,970 | ZCA1 |
| 2020 | High-resolution spatial transcriptomics through light patterning1R21CA246358-01 | SEELIG, GEORGWU, DAVID | UNIVERSITY OF WASHINGTON, WA | $218,089 | ZCA1 |
| 2020 | Label-Free Cell-Resolved Metabolomics for Tumor Microscopy1R21CA240214-01A1 | CICERONE, MARCUS T | GEORGIA INSTITUTE OF TECHNOLOGY, GA | $216,120 | ZCA1 |
| 2020 | High Throughput Digital Droplet ELISA for Ultrasensitive Multiplexed Diagnostics1R21CA236653-01A1 | ISSADORE, DAVID AARON | UNIVERSITY OF PENNSYLVANIA, PA | $213,288 | ZCA1 |
| 2020 | Development of a microfluidic primary cell editing platform (pCEP) for personal gene therapy1R21CA229024-01A1 | HUR, SOOJUNG CLAIRE | JOHNS HOPKINS UNIVERSITY, MD | $185,163 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.